Mirum Pharmaceuticals, Inc. (MIRM) — Financial statements
Income statement, balance sheet, and cash flow for Mirum Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 521↑54.7% | 337↑80.8% | 186↑141.8% | 77↑302.7% | 19 | |
| Cost of Revenue | 101↑23.2% | 82↑73.6% | 47↑280.1% | 12↑550.2% | 2 | |
| Gross Profit | 421↑64.8% | 255↑83.2% | 139↑115.4% | 65↑275.3% | 17 | |
| Operating Expenses | ||||||
| R&D Expenses | 186↑32.4% | 141↑37.1% | 103↓4.0% | 107↓18.7% | 131 | |
| General & Administrative Expenses | 0.00↓100.0% | 191↑36.6% | 140 | 0.00↓100.0% | 50 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 12↑82.5% | 6 | 0.00↓100.0% | 9 | |
| SG&A Expenses | 257↑27.1% | 202↑38.6% | 146↑63.8% | 89↑50.4% | 59 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 443↑29.3% | 343↑38.0% | 248↑26.8% | 196↑2.8% | 191 | |
| Total Costs & Expenses | 543↑28.0% | 424↑43.6% | 296↑41.9% | 208↑8.2% | 193 | |
| Operating Results | ||||||
| Operating Income | -22↑74.7% | -88↑19.7% | -109↑16.8% | -131↑24.3% | -173 | |
| Depreciation & Amortization | 24↑2.6% | 24↑118.2% | 11↑234.4% | 3↑232.1% | 0.98 | |
| EBITDA | 17↑135.1% | -49↑64.1% | -136↓11.1% | -123↓87.9% | -65 | |
| EBIT | -7↑90.3% | -73↑50.7% | -147↓16.8% | -126↓90.0% | -66 | |
| Interest & Other Income | ||||||
| Net Interest Income | -2↓220.2% | -0.52↑62.1% | -1↑88.7% | -12↑29.6% | -17 | |
| Interest Income | 13↓7.7% | 14↑0.4% | 14↑256.1% | 4↑953.8% | 0.37 | |
| Interest Expense | 14↑0.5% | 14↓5.3% | 15↓5.5% | 16↓9.2% | 18 | |
| Non-Operating Income | -15↓0.6% | -15↓139.3% | 38↑844.2% | -5↑95.2% | -107 | |
| Other Income / Expenses | 0.71↑2.2% | 0.69↑101.3% | -53↓390.9% | -11↓112.1% | 89 | |
| Income Before Tax | -21↑75.3% | -87↑46.5% | -162↓14.3% | -142↓69.2% | -84 | |
| Income Tax Expense | 2↑88.0% | 1↑3.9% | 0.99↑115.5% | -6↓17413.5% | 0.04 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -23↑73.4% | -88↑46.2% | -163↓20.5% | -136↓61.5% | -84 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -23↑73.4% | -88↑46.2% | -163↓20.5% | -136↓61.5% | -84 | |
| Bottom-Line Net Income | -23↑73.4% | -88↑46.2% | -163↓19.6% | -137↓62.6% | -84 | |
| EPS (Basic) | -0.47↑74.6% | -1.85↑53.8% | -4.00↑0.2% | -4.01↓44.8% | -2.77 | |
| EPS (Diluted) | -0.47↑74.6% | -1.85↑53.8% | -4.00↑0.5% | -4.02↓45.1% | -2.77 | |
| Weighted Average Shares | 50↑5.6% | 48↑16.2% | 41↑20.8% | 34↑11.6% | 30 | |
| Weighted Average Diluted Shares | 50↑5.6% | 48↑16.2% | 41↑20.3% | 34↑12.1% | 30 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.